HOOK

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Hookipa Pharma (HOOK – Research Report) today and set a price target of $6.00. The company's shares closed last Monday at $1.50, close to its 52-week low of $1.25. According to TipRanks.com, Buchanan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.1% and a 23.4% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and CureVac. Hookipa Pharma has an analyst consensus of Strong Buy, with a price target consensus of $6.33, implying a 305.8% upside from current levels.
https://www.tipranks.com/news/blurbs/jmp-securities-thinks-hookipa-pharmas-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral